CEO, Vida FLaSh Acquisitions
Frank is a co-founder of Pura Vida Investments and serves as Member, Director of Designated Investments. Frank has an extensive background in healthcare ranging from clinical practice and research to founding and operating companies. He currently serves as CEO of Vida FLaSH Acquisitions, Inc., a life sciences SPAC as well as co-managing member of FLaSH Investments LLC, the SPAC sponsor. He is Executive Chairman of Capricor, Inc., a publicly traded biotechnology firm developing novel therapeutics for treatment of heart failure, and a General Partner of Reprise Technologies, LLC, a medical device incubator. In addition he serves as a Director or Chairman of several privately held companies including V-Wave Ltd, a clinical stage medical device company focused on the treatment of heart failure, Credence Medsystems, a medical device company, and Levation Pharma Ltd, a facial aesthetics company. Until 2020, he served both on the Board of MedAvail Technologies, Inc, a healthcare technology company which became publicly traded on the NASDAQ, and as Director of Trialtech Medical, a software and services company which was sold to Scarrett Sciences. He was also a member of the Board of Directors of Recor Medical Inc, a medical device company in the field of renal denervation that was sold to Otsuka Pharmaceuticals in 2018. Frank served as Chairman & CEO of Conor Medsystems, a drug-eluting stent company that was sold to Johnson & Johnson for $1.4 billion in 2007. He was Chairman of Savacor, a maker of implantable remote pressure monitoring devices that was sold to St. Jude in 2005. Frank was Co-Founder and Chairman of Progressive Angioplasty, the developer of the stent delivery system for the Palmaz-Schatz stent marketed by Johnson & Johnson. The company was sold to US Surgical, which eventually was acquired by Covidien. Frank was a Director of One Lambda Inc., a leader in transplant diagnostics that was sold to Thermo Fisher Scientific Inc., in 2012 for $925 million. He was Co-Founder and Director of Advanced Interventional Systems Inc until its merger with The Spectranetics Corporation in 1993.
From 1986 until 2000, Frank was Co-Director of Cardiovascular Intervention at Cedars Sinai in Los Angeles. He attained the rank of Full Professor of Medicine at UCLA and Board Certification in Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. He has authored over 100 research articles and chapters on various areas of cardiology. Frank received his undergraduate and medical degrees from McGill University in Montreal, Canada. He resides and operates out of Los Angeles, CA.